Amendments to the Claims:

Please cancel claim 2 and amend claims 1, 3, and 32 as detailed below. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended)A genetically engineered hybrid polypeptide plasminogen activator ~~comprising a single polypeptide molecule having the following components: a) a plasminogen activating component comprising a streptokinase (SK), a modified SK, or portions of a SK capable of plasminogen activation, and b) fibrin binding component comprising regions of human fibronectin selected from the pair of fibrin binding domains 4 and 5, or domains 1 and 2, or modified forms thereof, the hybrid plasminogen activator possessing the ability to bind with fibrin independently, and plasminogen activation only after a lag in comparison to plasminogen activation by the plasminogen activating component alone~~ wherein said activator comprises a streptokinase (SK) or its functional component containing essentially polypeptide fragment corresponding to residues 16-383 of SK, whereby retaining up to 100% plasminogen activity, and finger-type fibrin binding domain (FBD) pairs of 1-2 and/or 4-5 of fibronectin or its functional components, bound specifically to N and/or C terminals of the SK, with the said activator showing a desired time-lag in plasminogen activation due to a plasmin-dependent activation mechanism.

2. Canceled

3. (Currently amended) [[~~An~~]] A hybrid plasminogen activator as claimed in claim 1, ~~which carries out plasminogen activation only after a lag period varying between 5 and 30 minutes after exposure of the plasminogen activator to a suitable animal or human plasminogen~~ wherein the time lag is ranging between 5 to 30 minutes.

32. (Currently amended) A pharmaceutical composition comprising a genetically engineered hybrid polypeptide plasminogen activator of claim 1, and stabilizer(s) ~~such as human serum albumin, mannitol etc. agents~~.